Composition for Topical Use

Abstract

The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.

1 - 13 . (canceled) 
     
     
         14 . A composition for topical use, transiently inducing activation of AhR receptors of skin tissues, said composition comprising an active substance selected from the group consisting of AhR agonist ligands with a short half-life and in situ precursors of said ligands. 
     
     
         15 . The composition as claimed in  claim 14 , wherein said active substance is selected from the group consisting of endogenous AhR ligands. 
     
     
         16 . The composition as claimed in  claim 14 , wherein said active substance is a precursor selected from the group consisting of the metabolic proligands of said AhR ligands. 
     
     
         17 . The composition as claimed in  claim 14 , wherein said active substance is a said precursor that is activable so as to give an AhR ligand under the effect of a physical agent. 
     
     
         18 . The composition as claimed in  claim 14 , wherein said active substance is a said precursor that is activable so as to give an AhR ligand under the effect of UV radiation. 
     
     
         19 . The composition as claimed in  claim 14 , wherein said active substance is a said precursor that is activable so as to give an AhR ligand under the effect of an endogenous agent present in the pathological condition treated. 
     
     
         20 . The composition as claimed in  claim 14 , wherein said active substance is a said precursor that is activable so as to give an AhR ligand under the effect of an exogenous agent present in the pathological condition treated. 
     
     
         21 . The composition as claimed in  claim 14 , wherein said ligands have half-lifetimes in the human organism of between 2 h and 96 h. 
     
     
         22 . The composition as claimed in  claim 14 , wherein said ligands have half-lifetimes in the human organism of between 6 h and 24 h. 
     
     
         23 . The composition as claimed in  claim 14 , wherein said active substance has:
 an ability to activate the AhR receptor,   an ability to modulate a gene regulated by AhR,   a short half-life in the human organism of between 2 hours and 96 h,   a measurable positive effect on a recognized criterion of sebaceous hyperactivity, of wound healing and of dermatoporosis, of bacterial colonization of the skin, and/or of estrogen deprivation.   
     
     
         24 . The composition as claimed in  claim 14 , for treating and/or preventing diseases comprising sebaceous gland hypertrophy. 
     
     
         25 . The composition as claimed in  claim 14 , for treating and/or preventing bacterial skin infections. 
     
     
         26 . The composition as claimed in  claim 14 , for treating and/or preventing diseases comprising skin colonization by bacterial species. 
     
     
         27 . The composition as claimed in  claim 14 , for treating and/or preventing diseases comprising Propionibacterium acnes and Staphylococcus aureus. 
     
     
         28 . The composition as claimed in  claim 14 , for treating and/or preventing skin function problems associated with estrogen deprivation. 
     
     
         29 . The composition as claimed in  claim 14 , for treating and healing skin wounds. 
     
     
         30 . The composition as claimed in  claim 14 , for treating and/or preventing skin atrophy. 
     
     
         31 . The composition as claimed in  claim 14 , for treating and/or preventing skin atrophy in the context of dermatoporosis. 
     
     
         32 . The composition as claimed in  claim 14 , wherein said active substance is selected from the group consisting of:
 Catechin,   Epigallocatechin 3-gallate,   Quercetin,   Apigenin,   Silibinin,   Resveratrol,   Yangonin,
 Tryptophan, 
   Indole-3-carbinol,   Tryptamine,   Kynurenine,   6-Formylindolo[3,2-b]carbazole (FICZ), alkyl and alkenyl derivatives of the formyl group, 3,3′-Diindolylmethane,   Tryptanthrine,   Malassezin,   Indirubin,   Indigo,   ITE [Methyl 2-(1′H-indole-3′-carbonyl)thiazole-4-carboxylate],   YH439 {(Isopropyl-2-(1,3-dithioethan-2-yl idene)-2-[N-(4-methylthiazol-2-yl)carbamoyl] acetate},   Hispidin,   alpha-Naphthoflavone,   beta-Naphthoflavone,   Ellipticine,   Carvedilol,   Triclabendazole,   Rutaecarpine,   Ethyl β-carboline-3-carboxylate and   Esomeprazole.